Educational Resources
EDUCATIONAL RESOURCES
KYSCO 2025 Inmunotherapy Meeting
Click on the session titles to view the recordings.
View the Agenda and Recorded TalksView KYSCO Oncology Voices Podcasts
Learn about CAR-T Cell Therapy in Earlier Lines of Treatment for Relapsed or Refractory Multiple Myeloma
Posted on 11/6/2025
To view the full publication, please refer to San-Miguel, J, et al. N Engl J Med. 2023;389(4):335-347 or click the resource below to view the Plain Language Summary of Publication of this article.
Pfizer | MyHealthcareFinances
Posted on 10/29/2025
MyHealthcareFinances is a freely available website to help patients and caregivers understand finances related to healthcare and steps that may lower costs. The site is a collaboration between Pfizer and Triage Cancer, joining people with a shared passion for improving healthcare-related financial literacy. Visit https://www.myhealthcarefinances.com/ for more information.
Pfizer Oncology Together
Posted on 10/29/2025
Live: Call 1-877-744-5675 (Monday–Friday 8 AM–8 PM ET)
Online: Visit http://PfizerOncologyTogether.com
Pfizer is committed to supporting patients throughout their treatment journey. With Pfizer Oncology Together, patients prescribed a Pfizer Oncology medication can get help identifying financial assistance options and be connected to resources that may help with some of their day-to-day challenges.
Pfizer Oncology Together can help healthcare providers by:
Assisting with benefits verification, prior authorizations, appeals, billing and coding, and specialty pharmacy coordination
Connecting them and their office staff to a Pfizer Field Reimbursement Manager (FRD) who can help address specific access and reimbursement issues—in person or over the phone
Offering and assisting with online portals that provide registered users with access and financial assistance resources
Pfizer Oncology Together can help patients by:
Connecting them with financial assistance resources—regardless of their insurance coverage
Providing personalized support from a Pfizer Oncology FRM who can help identify resources and organizations that may provide additional assistance
Please visit http://PfizerOncologyTogether.com for more details, or contact your local FRM or AP&R Director to learn more.
© 2024 Pfizer Inc. All rights reserved. PP-UNP-USA-4653 September 2024
Explore emerging real-world evidence in front-line BPDCN
This new publication explores real-world safety and efficacy in patients treated with a CD123 targeted therapy in newly diagnosed blastic plasmacytoid dendritic cell neoplasms.
A Phase 3 Study of elacestrant versus standard endocrine therapy in node-positive ER+, HER2- early breast cancer with high risk of recurrence (ELEGANT)
Posted on 05/14/2025
Despite advances in the adjuvant treatment of early-stage estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer, there continues to be a risk of recurrence. The ELEGANT study is a Global, Multicenter, Randomized, Open-label Phase 3 Study with the primary goal to evaluate the efficacy and safety of elacestrant versus standard endocrine therapy in participants with node-positive ER+/HER2- early breast cancer with high risk of recurrence. The main purpose of this study is to compare the Invasive Breast Cancer-Free Survival (IBCFS) over a period of up to 5 years. 4220 participants will be included in this study around the world. Participants will have equal chance to be assigned to receive either of the treatment combinations.
Anemia in Focus: The Challenge of Identifying Myelodysplastic Syndromes (MDS)
Posted on 11/09/2024
Anemia is a hallmark of MDS, conferring heightened mortality risk and diminished quality of life. Please feel free to view & share this important resource.
Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups
Posted on 11.11.2024
Elacestrant significantly prolonged progression-free survival (PFS) with manageable safety versus standard-of-care (SOC) endocrine therapy (ET) in patients with estrogen receptor–positive (ER+), HER2− metastatic breast cancer and tumors harboring estrogen receptor 1 (ESR1) mutation following ET plus a cyclin-dependent kinase 4/6 inhibitor (ET+CDK4/6i).
ESR1 Mutations in ER+/HER2 - Metastatic Breast Cancer
Published on: June 26, 2024
Nearly 1 out of 2 people with ER+/HER2- metastatic breast cancer may develop an ESR1 mutation after progression on hormone therapy. Learn more about this ESR1 mutation at http://Knowesr1.com.
Diagnosis and Treatment of Hematologic Cancer
Published on: June 26, 2024
BPDCN is a cancer that affects your blood and the soft tissue inside your bones, which is called bone marrow. It can also affect other parts of your body, such as your lymph nodes, spleen, central nervous system, and skin. Learn more about this hematologic disease at https://BPDCNinfo.com.
New Resources for Acute Myeloid Leukemia Care Providers
To improve outcomes for patients with acute myeloid leukemia, especially those who do not receive a transplant, the Association of Cancer Care Centers (ACCC), with support from Bristol Myers Squibb, has partnered with the HealthTree Foundation for Acute Myeloid Leukemia to develop a suite of resources, including:
Cancer Buzz Podcast Series
ACCC Buzz Educational Blog Series
Comprehensive Effective Practices Guide